

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **December 1, 2023**, updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the **December 1, 2023**, updates for complete listings of products available by special authorization, step therapy/special authorization, changes to criteria for coverage, restricted benefits, added products, least cost alternative price changes, products with a price change and discontinued listings.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Apo-Prednisone 5 mg Tablet (DIN 00312770) manufactured by Apotex Inc., **Teva-Prednisone 5 mg Tablet (DIN 00021695)** manufactured by Teva Canada Limited will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **November 11, 2023**.

As of **November 11, 2023**, all claims for **Teva-Prednisone 5 mg Tablet (DIN 00021695)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Isopto Atropine 1% Ophthalmic Solution (DIN 00035017) manufactured Alcon Canada Inc., **Atropine Sulfate 1% Ophthalmic Solution (Minims) (DIN 02148358)** manufactured by Bausch and Lomb Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for of Isopto Atropine 1% Ophthalmic Solution (DIN 00035017) has been resolved.

Atropine Sulfate 1% Ophthalmic Solution (Minims) (DIN 02148358) will no longer be considered a temporary benefit for the *ADBL* **after December 22, 2023**. The above grouping was removed from the Critical Supply Product List **November 22, 2023**.

Due to the shortage of Folic Acid 5 mg Tablet (DIN 00426849) manufactured by AA Pharma Inc. and Jamp-Folic 5 mg Tablet (DIN 02366061), **Folic Acid 1 mg Tablet (DIN 00318973)** manufacturer by C.E. Jamieson & Co. Ltd. and **Jamp-Folic Acid 1 mg Tablet (NPN 80053274)** were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)* .

Alberta Blue Cross has confirmed that the shortage of Folic Acid 5 mg Tablet (DIN 00426849) has been resolved.

Folic Acid 1 mg Tablet (DIN 00318973) and **Jamp-Folic Acid 1 mg Tablet (NPN 80053274)** will no longer be considered as temporary benefits for the *ADBL* **after December 22, 2023**. The above grouping was removed from the Critical Supply Product List **November 23, 2023**.

continued next page

PHARMACY BENEFACT

continued from previous page

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has confirmed that the shortages for Apo-Mometasone 50 mcg/dose Aqueous Nasal Spray (DIN 02403587), Mometasone 50 mcg/dose Aqueous Nasal Spray (DIN 02519127) manufactured by Sanis Health Inc., Sandoz Mometasone 50 mcg/dose Aqueous Nasal Spray (DIN 02449811) and Teva-Mometasone 50 mcg/dose Aqueous Nasal Spray (DIN 02475863) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 22, 2023**. The following grouping was removed from the Critical Supply Product List **November 22, 2023**.

MOMETASONE FUROATE

50 MCG / DOSE NASAL METERED DOSE SPRAY

00002403587	APO-MOMETASONE	APX	\$ 0.0752
00002519127	MOMETASONE	SNS	\$ 0.0752
00002449811	SANDOZ MOMETASONE	SDZ	\$ 0.0752
00002475863	TEVA-MOMETASONE	TEV	\$ 0.0752
00002238465	NASONEX	ORC	\$ 0.2148

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

